The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure
Meaghan O’Connor,Kristen Hsu,Lynne Broderick,Kristen L McCausland,Kaitlin LaGasse,Sabrina Rebello,Michelle Carty,Isabelle Lousada
DOI: https://doi.org/10.2147/PROM.S411721
2023-07-08
Patient Related Outcome Measures
Abstract:Meaghan O'Connor, 1 Kristen Hsu, 2 Lynne Broderick, 1 Kristen L McCausland, 1 Kaitlin LaGasse, 1 Sabrina Rebello, 2 Michelle Carty, 1 Isabelle Lousada 2 1 QualityMetric Incorporated LLC, Johnston, RI, USA; 2 Amyloidosis Research Consortium, Newton, MA, USA Correspondence: Kristen Hsu, Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA, Tel +1-617-467-5170, Email Purpose: Patients with transthyretin amyloidosis (ATTR) experience a wide variety of symptoms and impacts on health-related quality of life (HRQoL). However, the lack of an ATTR-specific patient-reported outcome (PRO) measure has made consistent measurement of HRQoL in ATTR challenging. This paper describes the development of a conceptual model and subsequent content for the Transthyretin Amyloidosis – Quality of Life Questionnaire (ATTR-QOL), an ATTR-specific PRO measure. Methods: This was a cross-sectional, non-interventional, US-based study. The study design included three stages: 1) a targeted literature review followed by qualitative data collection with patients and experts; 2) development of a conceptual model and PRO measure; and 3) review of the PRO measure using a modified Delphi method, translatability assessment, and interviews with patients and experts. Revisions were made to the measure after each round of review. Results: Forty-four patients and 29 experts participated in this study. The conceptual model included two primary concepts of interest: symptoms (cardiac, neuropathic–peripheral, neuropathic–autonomic, and other) and impacts (eg, physical, role, and mental/emotional functioning). Seventy-two items were created (32 symptoms; 40 impacts) to align with the model. A recall period of one month was selected based on participant input. Conclusion: The ATTR-QOL was created with significant patient involvement and guidance from a multidisciplinary group of experts. The mix of patient and clinical perspectives helped to ensure a balanced representation of all relevant disease experiences and clinical specialties. With further refinement from psychometric testing, the ATTR-QOL will provide a standard, comprehensive measure for all ATTR-specific research including both clinical trials and clinical practice. Keywords: content validity, cardiomyopathy, polyneuropathy, qualitative, clinical outcome assessment Transthyretin amyloidosis (ATTR) is a rare, debilitating disease caused by deposits of misfolded transthyretin proteins in organ systems. There are two types of ATTR: hereditary and wild-type. 1 Hereditary ATTR (hATTR or ATTRv) includes more than 120 genotypes and can be further subtyped into cardiomyopathy (hATTR-CM) and polyneuropathy (hATTR-PN) based on the primary organ systems affected. 2 The most commonly observed genotype worldwide, V30M, is primarily associated with symptoms of polyneuropathy and was first described in a population of patients in Portugal. 3–5 The most commonly observed genotype in the United States, V122I, is typically found in African Americans and is primarily associated with symptoms of cardiomyopathy. 4,6,7 It should be noted that as research continues and more variants are better understood, evidence suggests that patients with hATTR may also experience ocular and/or central nervous system involvement. 8–10 Wild-type ATTR (ATTRwt) is not caused by any of the known genetic mutations; rather, it typically develops in older age and most often results in cardiomyopathy. Regardless of type, the clinical presentation of ATTR is complex: patients experience a wide variety of symptoms, 11–16 and, in turn, many impacts on daily life, including on work, healthcare resource utilization, and overall health-related quality of life (HRQoL). 14,17–19 A 2018 multidisciplinary stakeholder meeting hosted by the Amyloidosis Research Consortium (ARC) identified the need for improved understanding and measurement of HRQoL in ATTR as an important research priority in this disease area. 20 To date, the lack of an ATTR-specific patient-reported outcome (PRO) measure has hindered the ATTR community's ability to measure HRQoL in a consistent, comprehensive way. Clinicians, researchers, drug developers, regulatory bodies, and payer evaluation organizations have relied on a combination of PRO measures intended for other conditions to measure symptoms, impacts, and overall HRQoL (eg, Norfolk-QOL-Diabetic Neuropathy, COMPASS-31, Kansas City Cardiomyopathy Questionnaire [KCCQ], SF-36). 21 While these instruments have value for the research and treatment of ATTR, the lack of specific attribution to the disease results in gaps in -Abstract Truncated-